ANI Pharmaceuticals (NASDAQ:ANIP) CEO Sells $383,400.00 in Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) CEO Nikhil Lalwani sold 5,400 shares of the stock in a transaction that occurred on Tuesday, September 15th. The shares were sold at an average price of $71.00, for a total value of $383,400.00. Following the sale, the chief executive officer directly owned 339,089 shares of the company’s stock, valued at $24,075,319. The trade was a 1.57% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Nikhil Lalwani also recently made the following trade(s):

• On Tuesday, August 25th, Nikhil Lalwani sold 5,400 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $74.30, for a total value of $401,220.00.

ANI Pharmaceuticals Price Performance

ANIP opened at $76.14 on Friday. The firm has a market cap of $1.75 billion, a P/E ratio of 16.41 and a beta of 0.45. The company has a debt-to-equity ratio of 0.99, a quick ratio of 2.41 and a current ratio of 2.91. ANI Pharmaceuticals, Inc. has a fifty-two week low of $69.58 and a fifty-two week high of $98.04. The firm has a 50-day moving average of $76.18 and a 200 day moving average of $78.11.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its earnings results on Friday, August 7th. The specialty pharmaceutical company reported $2.21 earnings per share for the quarter, beating analysts’ consensus estimates of $2.04 by $0.17. ANI Pharmaceuticals had a net margin of 11.07% and a return on equity of 27.37%. The firm had revenue of $266.04 million for the quarter, compared to analysts’ expectations of $260.13 million. During the same period in the previous year, the company earned $1.80 earnings per share. The company’s quarterly revenue was up 25.8% on a year-over-year basis. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. On average, research analysts expect that ANI Pharmaceuticals, Inc. will post 7.83 EPS for the current year.

Hedge Funds Weigh In On ANI Pharmaceuticals

Several hedge funds have recently bought and sold shares of the company. Ranger Investment Management L.P. purchased a new position in shares of ANI Pharmaceuticals during the 2nd quarter valued at $28,406,000. Deutsche Bank AG bought a new stake in ANI Pharmaceuticals during the second quarter valued at $26,775,000. William Blair Investment Management LLC purchased a new position in ANI Pharmaceuticals during the second quarter worth about $21,372,000. Parkman Healthcare Partners LLC purchased a new position in ANI Pharmaceuticals during the second quarter worth about $16,797,000. Finally, Bank of America Corp DE bought a new position in ANI Pharmaceuticals in the 2nd quarter worth about $15,154,000. Hedge funds and other institutional investors own 76.05% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on ANIP. Canaccord Genuity Group cut their target price on shares of ANI Pharmaceuticals from $91.00 to $90.00 and set a “hold” rating for the company in a research report on Monday, August 10th. Weiss Ratings cut shares of ANI Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Tuesday, August 11th. Leerink Partners began coverage on shares of ANI Pharmaceuticals in a report on Wednesday, September 9th. They issued an “outperform” rating and a $104.00 price objective for the company. Guggenheim cut their price objective on shares of ANI Pharmaceuticals from $124.00 to $119.00 and set a “buy” rating for the company in a report on Monday, August 10th. Finally, Wall Street Zen lowered shares of ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday, August 8th. Four investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, ANI Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $103.00.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a specialty pharmaceutical company that develops, manufactures and markets branded and generic prescription medicines. The company focuses on products with complex formulations, manufacturing requirements or specialized commercial opportunities, and serves a range of therapeutic areas.

ANI’s portfolio includes Cortrophin-Zinc, a repository corticotropin injection used for certain autoimmune and inflammatory conditions, along with a selection of branded and generic medicines.